# PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

> **NCT02557321** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Provectus Biopharmaceuticals, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** PV-10
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02557321
- **Lead sponsor:** Provectus Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2023-05
- **Final completion:** 2025-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02557321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02557321, "PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02557321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*